A Phase 2/3 Randomized Double-blind Placebo-controlled Multicenter Prospective Study to Assess the Efficacy Safety and Pharmacokinetics of Orally Administered Epetraborole in Patients with Treatment-refractory Mycobacterium avium Complex Lung Disea

Brief description of study

A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter, Prospective Study to Assess the Efficacy, Safety, and Pharmacokinetics of Orally Administered Epetraborole in Patients with Treatment-refractory Mycobacterium avium Complex Lung Disea


Clinical Study Identifier: s22-00181
ClinicalTrials.gov Identifier: NCT05327803
Principal Investigator: Doreen J Addrizzo-Harris.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.